Managers / Q1 2026
TRV GP IV, LLC
CIK 0001688325 · 201 BROOKLINE AVE, SUITE 1401, BOSTON, MA, 02215 · 617-585-2000
Summary
Trv GP IV, LLC reported $267M in U.S.-listed holdings across 2 positions for Q1 2026.
The portfolio is heavily concentrated: MAZE alone accounts for 50.0% of reported value.
The book was largely unchanged from Q4 2025.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 100.0% · $267M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| TNGXTANGO THERAPEUTICS, INC. | TRIMMED | −1.50M | 6.37M | +$64M | $133M |
| MAZEMAZE THERAPEUTICS, INC. | HELD | +0 | 4.47M | −$52M | $134M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | MAZEMAZE THERAPEUTICS, INC.history → | COM | 50.04% | $134M | 4.47M |
| 2 | TNGXTANGO THERAPEUTICS, INC.history → | COM | 49.96% | $133M | 6.37M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $267M | 2 | May 7, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $255M | 2 | Feb 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $274M | 2 | Nov 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $163M | 3 | Aug 8, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $93M | 3 | May 9, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $80M | 2 | Feb 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $162M | 3 | Nov 6, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $202M | 3 | Aug 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $206M | 3 | May 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $246M | 3 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $265M | 3 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $111M | 3 | Aug 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $140M | 3 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $235M | 5 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $171M | 5 | Nov 3, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $152M | 5 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $273M | 5 | May 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $348M | 5 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $441M | 5 | Nov 5, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $210M | 4 | Aug 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $271M | 4 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $312M | 5 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $290M | 5 | Nov 6, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $217M | 4 | Aug 7, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $109M | 3 | May 11, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $160M | 2 | Feb 5, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $98M | 2 | Nov 4, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $118M | 1 | Aug 6, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $132M | 1 | May 3, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $46M | 1 | Jan 28, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.